Page last updated: 2024-11-02

pirenzepine and Dizzyness

pirenzepine has been researched along with Dizzyness in 2 studies

Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Research Excerpts

Excerpt	Relevance	Reference
"Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized."	4.79	Safety of olanzapine. ( Beasley, CM; Tollefson, GD; Tran, PV, 1997)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beasley, CM	1
Tollefson, GD	1
Tran, PV	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936]			Phase 4	16 participants (Actual)	Interventional	2005-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Body Mass Index (BMI)

Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Intervention	kg/m^2 (Mean)
Aripiprazole	-0.4
Placebo	0.3

Change From Baseline in Fasting Total Cholesterol

Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Intervention	mg/dL (Mean)
Aripiprazole	-3
Placebo	9

Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)

Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Intervention	mg/dL (Mean)
Aripiprazole	0.4
Placebo	0.6

Change From Baseline in Low-density Lipoprotein (LDL)

Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Intervention	mg/dL (Mean)
Aripiprazole	-0.2
Placebo	3.1

Change From Baseline in Triglycerides

Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Intervention	mg/dL (Mean)
Aripiprazole	-51.7
Placebo	47.6

Change From Baseline in Waist-hip Ratio (WHR)

Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Intervention	cm (Mean)
Aripiprazole	0.0
Placebo	0.0

Change From Baseline in Weight (Lbs)

Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Intervention	lbs (Mean)
Aripiprazole	-2.9
Placebo	2.1

Reviews

1 review available for pirenzepine and Dizzyness

Article	Year
Safety of olanzapine. The Journal of clinical psychiatry, 1997, Volume: 58 Suppl 10 Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Clini	1997

Trials

1 trial available for pirenzepine and Dizzyness

Article	Year
Olanzapine for schizophrenia. The Medical letter on drugs and therapeutics, 1997, Jan-17, Volume: 39, Issue:992 Topics: Antipsychotic Agents; Benzodiazepines; Constipation; Costs and Cost Analysis; Dizziness; Dose-Respon	1997